Analogous to the situation in human medicine, contemporary practices in horse management, which incorporate lengthy periods of physical inactivity coupled with provision of nutritional rations characterized by inappropriately high sugar and starch, have led to obesity being more commonly recognized by practitioners of equine veterinary practice. In many of these cases, obesity is associated with insulin resistance (IR) and glucose intolerance. An equine metabolic syndrome (MS) has been described that is similar to the human MS in that both IR and aspects of obesity represent cornerstones of its definition.
Unlike its human counterpart, Identification of the equine metabolic syndrome (EMS) portends greater risk for development of laminitis, a chronic, crippling affliction of the equine hoof. When severe, laminitis sometimes necessitates euthanasia. Unlike the human condition, the risk of developing type 2 diabetes mellitus and many other chronic conditions, for which the risk is recognized as increased in the face of MS, is less likely in horses. The equine veterinary literature has been replete with reports of scientific investigations regarding the epidemiology, pathophysiology, and treatment of EMS.
JohnsonPJ. The equine metabolic syndrome peripheral Cushing's syndrome. Vet Clin North Am Equine Pract.2002;18 (2): 271–93.
2.
FrankNGeorRJBaileySRDurhamAEJohnsonPJ; American College of Veterinary Internal Medicine. Equine metabolic syndrome. J Vet Intern Med.2010;24 (3): 467–75.
3.
FrankN. Equine metabolic syndrome. Vet Clin North Am Equine Pract.2011;27 (1): 73–92.
4.
AlbertiKGZimmetPShawJ. Metabolic syndrome–a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med.2006;23 (5): 469–80.
5.
DayC. Metabolic syndrome, or what you will: Definitions and epidemiology. Diab Vasc Dis Res.2007;4 (1): 32–8.
6.
MeigsJBRutterMKSullivanLMFoxCSD'AgostinoRBSrWilsonPW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care.2007;30 (5): 1219–25.
7.
MottilloSFilionKBGenestJJosephLPiloteLPoirierPRinfretSSchiffrinELEisenbergMJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol.2010;56 (14): 1113–32.
8.
De NunzioCAronsonWFreedlandSJGiovannucciEParsonsJK. The Correlation Between Metabolic Syndrome and Prostatic Diseases. Eur Urol.2012;61 (3): 560–70.
9.
HammarstenJPeekerR. Urological aspects of the metabolic syndrome. Nat Rev Urol.2011;8 (9): 483–94.
10.
FraileJMPuigJGTorresRJde MiguelEMartínezPVázquezJJ. Uric acid metabolism in patients with primary gout and the metabolic syndrome. Nucleosides Nucleotides Nucleic Acids.2010;29 (4–6): 330–4.
11.
BaranovaATranT PBirerdincAYounossiZM. Systematic review: Association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther.2011;33 (7): 801–14.
12.
LurieA. Metabolic disorders associated with obstructive sleep apnea in adults. Adv Cardiol.2011;46: 67–138.
13.
GallagherEJLeroithDKarnieliE. The metabolic syndrome–from insulin resistance to obesity and diabetes. Med Clin North Am.2011;95 (5): 855–73.
14.
García-LaraJMAguilar-NavarroSGutiérrez-RobledoLMAvila-FunesJA. The metabolic syndrome, diabetes, and Alzheimer's disease. Rev Invest Clin.2010;62 (4): 343–9.
15.
McGinleyBPunjabiNM. Obesity, metabolic abnormalities, and asthma: Establishing causal links. Am J Respir Crit Care Med.2011;183 (4): 424–5.
16.
ChangYSungERyuSParkYWJangYMParkM. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci.2008;23 (4): 644–50.
17.
ScorlettiECalderPCByrneCD. Non-alcoholic fatty liver disease and cardiovascular risk: Metabolic aspects and novel treatments. Endocrine.2011;40 (3): 332–43.
18.
GottliebABDannF. Comorbidities in patients with psoriasis. Am J Med.2009;122 (12): 1150.e1–9.
19.
VickMMAdamsAAMurphyBASessionsDRHorohovDWCookRFSheltonBJFitzgeraldBP. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse. J Anim Sci.2007;85 (5): 1144–55.
20.
VickMMMurphyBASessionsDRReedySEKennedyELHorohovDWCookRFFitzgeraldBP. Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. Am J Vet Res.2008;69 (1): 130–9.
21.
BaileySRHabershon-ButcherJLRansomKJElliottJMenzies-GowNJ. Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis. Am J Vet Res.2008;69 (1): 122–9.
22.
RughKSGarnerHESprouseRFHatfieldDG. Left ventricular hypertrophy in chronically hypertensive ponies. Lab Anim Sci.1987;37 (3): 335–8.
23.
CarterRATreiberKHGeorRJDouglassLHarrisPA. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J.2009;41 (2): 171–8.
24.
JohnsonPJWiedmeyerCEMesserNTGanjamVK. Medical implications of obesity in horses–lessons for human obesity. J Diabetes Sci Technol.2009;3 (1): 163–74.
25.
WaittLHCebraCK. Characterization of hypertriglyceridemia and response to treatment with insulin in horses, ponies, and donkeys: 44 cases (1995–2005). J Am Vet Med Assoc.2009;234 (7): 915–9.
26.
RalstonSL. Hyperglycemia/hyperinsulinemia after feeding a meal of grain to young horses with osteochondritis dissecans (OCD) lesions. Pferdeheilkunde.1996;12: 320–2.
27.
DurhamAEHughesKJCottleHJRendleDIBostonRC. Type 2 diabetes mellitus with pancreatic beta cell dysfunction in 3 horses confirmed with minimal model analysis. Equine Vet J.2009;41 (9): 924–9.
28.
JohnsonPJScottyNCWiedmeyerCMesserNTKreegerJM. Diabetes mellitus in a domesticated Spanish mustang. J Am Vet Med Assoc.2005;226 (4): 584–8.
29.
Yki-JärvinenH. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig Dis.2010;28 (1): 203–9.
30.
StogdaleL. Definition of diabetes mellitus. Cornell Vet.1986;76 (2): 156–74.
31.
KuzuyaTNakagawaSSatohJKanazawaYIwamotoYKobayashiMNanjoKSasakiASeinoYItoCShimaKNonakaKKadowakiT; Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract.2002;55 (1): 65–85.
32.
MesserNT4thJohnsonPJ. Evidence-based literature pertaining to thyroid dysfunction and Cushing's syndrome in the horse. Vet Clin North Am Equine Pract.2007;23 (2): 329–64.
33.
McFarlaneDDybdalNDonaldsonMTMillerLCribbAE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol.2005;17 (2): 73–80.
34.
McFarlaneD. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res Rev.2007;6 (1): 54–63.
35.
McGowanCMFrostRPfeifferDUNeigerR. Serum insulin concentrations in horses with equine Cushing's syndrome: Response to a cortisol inhibitor and prognostic value. Equine Vet J.2004;36 (3): 295–8.
36.
JorgensonGE. Interesting case of pancreatic glycosurea. J Am Vet Med Assoc.1921;58: 718–9.
37.
JeffreyJR. Diabetes mellitus secondary to chronic pancreatitis in a pony. J Am Vet Med Assoc.1968;153 (9): 1168–75.
38.
BulginMSAndersonBC. Verminous arteritis and pancreatic necrosis with diabetes mellitus in a pony. Compend Contin Educ Pract Vet.1983;5: S482–S285.
39.
McCoyDJ. Diabetes mellitus associated with bilateral granulosa cell tumors in a mare. J Am Vet Med Assoc.1986;188 (7): 733–5.
40.
GiriJKMagdesianKGGaffneyPM. Insulin-dependent diabetes mellitus associated with presumed autoimmune polyendocrine syndrome in a mare. Can Vet J.2011;52 (5): 506–12.
41.
RuoffWWBakerDCMorganSJAbbittB. Type II diabetes mellitus in a horse. Equine Vet J.1986;18 (2): 143–4.
42.
TaskerJBWhitemanCEMartinBR. Diabetes mellitus in the horse. J Am Vet Med Assoc.1966;149 (4): 393–9.
43.
BakerJRRitchieHE. Diabetes mellitus in the horse: A case report and review of the literature. Equine Vet J.1974;6 (1): 7–11.
44.
MuylleEvan den HendeCDeprezPNuyttenJOyaertW. Non-insulin dependent diabetes mellitus in a horse. Equine Vet J.1986;18 (2): 145–6.
45.
Navas de Solis C, Foreman JH. Transient diabetes mellitus in a neonatal Thoroughbred foal. J Vet Emerg Crit Care (San Antonio).;2010;20 (6): 611–5.
YangJKLinSSJiXJGuoLM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol.2010;47 (3): 193–9.
48.
CraigheadJE. The role of viruses in the pathogenesis of pancreatic disease and diabetes mellitus. Prog Med Virol.1975;19: 161–214.
49.
BallottiSde MartinoM. Rotavirus infections and development of type 1 diabetes: An evasive conundrum. J Pediatr Gastroenterol Nutr.2007;45 (2): 147–56.
50.
Van der Werf N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev.;2007;23 (3): 169–83.
51.
ScroggieDAAlbrightAHarrisMD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med.2003;163 (13): 1587–90.
52.
KuzuyaTNakagawaSSatohJKanazawaYIwamotoYKobayashiMNanjoKSasakiASeinoYItoCShimaKNonakaKKadowakiT; Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract.2002;55 (1): 65–85.
53.
KumarPRBhansaliARavikiranMBhansaliSDuttaPThakurJSSachdevaNBhadadaSKWaliaR. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: A community-based study. J Clin Endocrinol Metab.2010;95 (6): 2832–5.
54.
TinworthKDWynnPCBostonRCHarrisPASillenceMNThevisMThomasANobleGK. Evaluation of commercially available assays for the measurement of equine insulin. Domest Anim Endocrinol.2011;41 (2): 81–90.
55.
JohnsonPJWiedmeyerCELaCarrubbaAGanjamVKMesserNT4th. Laminitis and the equine metabolic syndrome. Vet Clin North Am Equine Pract.2010;26 (2): 239–55.
56.
EilerHFrankNAndrewsFMOliverJWFecteauKA. Physiologic assessment of blood glucose homeostasis via combined intravenous glucose and insulin testing in horses. Am J Vet Res.2005;66 (9): 1598–604.
57.
SchuverA. Use of an oral sugar test to assess insulin sensitivity in healthy and insulin resistant horses [abstract]. J Vet Intern Med.2010;24 (3): 780.
58.
WiedmeyerCEJohnsonPJCohnLAMeadowsRL. Evaluation of a continuous glucose monitoring system for use in dogs, cats, and horses. J Am Vet Med Assoc.2003;223 (7): 987–92.
59.
WiedmeyerCEJohnsonPJCohnLAMeadowsRLKerlMETessmanRKPerlisJDeClueAE. Evaluation of a continuous glucose monitoring system for use in veterinary medicine. Diabetes Technol Ther.2005;7 (6): 885–95.
60.
JohnsonPJWiedmeyerCELaCarrubbaAMesserNTDingfelderHACogswellAMAmorimJRGanjamVK. Clinical assessment of blood glucose homeostasis in horses: Comparison of a continuous glucose monitoring system with a combined intravenous glucose and insulin test protocol. J Vet Intern Med.2011;25 (1): 162–5.
61.
CarterRATreiberKHGeorRJDouglassLHarrisPA. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J.2009;41 (2): 171–8.
62.
PowellDMReedySESessionsDRFitzgeraldBP. Effect of short-term exercise training on insulin sensitivity in obese and lean mares. Equine Vet JSuppl.2002; (34): 81–4.
63.
LacombeVAHinchcliffKWDevorST. Effects of exercise and glucose administration on content of insulin-sensitive glucose transporter in equine skeletal muscle. Am J Vet Res.2003;64 (12): 1500–6.
64.
NoutYSHinchcliffKWJose-CunillerasEDearthLRSivkoGSDeWilleJW. Effect of moderate exercise immediately followed by induced hyperglycemia on gene expression and content of the glucose transporter-4 protein in skeletal muscles of horses. Am J Vet Res.2003;64 (11): 1401–8.
65.
SandovalDAGuyDLRichardsonMAErtlACDavisSN. Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes.2004;53 (7): 1798–806.
66.
GiannarelliRAragonaMCoppelliADel PratoS. Reducing insulin resistance with metformin: The evidence today. Diabetes Metab.2003;29 (4 Pt 2): 6S28–35.
67.
MarchettiPDel GuerraSMarselliLLupiRMasiniMPolleraMBuglianiMBoggiUVistoliFMoscaFDel PratoS. Pancreatic islets from type 2 diabetic patients have functional deffects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab.2004;89 (11): 5535–41.
68.
HustaceJLFirshmanAMMataJE. Pharmacokinetics and bio-availability of metformin in horses. Am J Vet Res.2009;70 (5): 665–8.
69.
WearnJMCrismanMVDavisJLGeorRJHodgsonDRSuageeJKAshraf-KhorassaniMMcCutcheonLJ. Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. J Vet Pharmacol Ther.2011;34 (3): 252–8.
70.
WearnJGSuageeJKCrismanMVCorlBAHulverMWHodgsonDRGeorRJMcCutcheonLJ. Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses. Vet Immunol Immunopathol.2012;145 (1–2): 42–9.
71.
SuageeJKCorlBAWearnJGCrismanMVHulverMWGeorRJMcCutcheonLJ. Effects of the insulin-sensitizing drug pioglitazone and lipopolysaccharide administration on insulin sensitivity in horses. J Vet Intern Med.2011;25 (2): 356–64.
